[go: up one dir, main page]

CO5160250A1 - Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen - Google Patents

Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen

Info

Publication number
CO5160250A1
CO5160250A1 CO00014724A CO00014724A CO5160250A1 CO 5160250 A1 CO5160250 A1 CO 5160250A1 CO 00014724 A CO00014724 A CO 00014724A CO 00014724 A CO00014724 A CO 00014724A CO 5160250 A1 CO5160250 A1 CO 5160250A1
Authority
CO
Colombia
Prior art keywords
group
alkyl
alkyl group
hydrogen
phenyl
Prior art date
Application number
CO00014724A
Other languages
English (en)
Inventor
Alistair Lochead
Frederic Galli
Samir Jegham
Axelle Samson
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO5160250A1 publication Critical patent/CO5160250A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compuesto, en forma de isómero geométrico u óptico puro o de mezcla de tales isómeros, de formula general (I)<EMI FILE="00014724_1" ID="1" IMF=JPEG >en la cualR1 representa un átomo de hidrógeno, un grupo (C1-C4) alquilo, un grupo fenil (C1-C4) alquilo, un grupo fenilhidroxi (C1-C4) alquilo, un grupo furanil (C1-C4)alquilo o un grupo furanilhidroxi (C1-C4)alquilo, R2 representa ya sea un átomo de hidrógeno o de halógeno o un grupo trifluorometilo, ciano, hidroxi, nitro, acetilo, (C1-C6)alquilo, (C1-C6)alcoxi o un grupo de fórmula general NR4R5 en la cual R4 representa un átomo de hidrógeno o un grupo (C1-C4)alquilo o (C1-C4)alcanoilo y R5 representa un átomo de hidrógeno o un grupo (C1-C4)alquilo, o bien R4 y R5 forman, con el átomo de nitrógeno que los contiene, un ciclo en C4-C7 ya sea un grupo fenilo o naftilo eventualmente sustituido por un átomo de halógeno o un grupo trifluorometilo, trifluorometoxi, ciano, hidroxi, nitro, acetilo, (C1-C6)alquilo, (C1-C6) alcoxi, metilendioxi enlazado en las posiciones 2 y 3 del ciclo fenilo y R3 representa un átomo de hidrógeno o de halógeno o un grupo (C1-C4)alquilo, en estado de base o de sal de adición a un ácido.
CO00014724A 1999-03-05 2000-03-01 Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen CO5160250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902784A FR2790474B1 (fr) 1999-03-05 1999-03-05 Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CO5160250A1 true CO5160250A1 (es) 2002-05-30

Family

ID=9542888

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00014724A CO5160250A1 (es) 1999-03-05 2000-03-01 Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen

Country Status (37)

Country Link
US (2) US6538003B1 (es)
EP (1) EP1161434B1 (es)
JP (1) JP4806123B2 (es)
KR (2) KR20070086359A (es)
CN (1) CN1137894C (es)
AR (1) AR022820A1 (es)
AT (1) ATE231869T1 (es)
AU (1) AU764625B2 (es)
BG (1) BG65211B1 (es)
BR (1) BR0008763A (es)
CA (1) CA2372063C (es)
CO (1) CO5160250A1 (es)
CZ (1) CZ302259B6 (es)
DE (1) DE60001307T2 (es)
DK (1) DK1161434T3 (es)
EE (1) EE04497B1 (es)
ES (1) ES2191611T3 (es)
FR (1) FR2790474B1 (es)
HK (1) HK1040398B (es)
HR (1) HRP20010655B1 (es)
HU (1) HU228671B1 (es)
ID (1) ID30116A (es)
IL (2) IL145150A0 (es)
MX (1) MXPA01008972A (es)
NO (1) NO327119B1 (es)
NZ (1) NZ513561A (es)
PE (1) PE20001543A1 (es)
PL (1) PL201683B1 (es)
RS (1) RS49997B (es)
RU (1) RU2238273C2 (es)
SK (1) SK284339B6 (es)
TR (1) TR200102403T2 (es)
TW (1) TWI222975B (es)
UA (1) UA61164C2 (es)
UY (1) UY26048A1 (es)
WO (1) WO2000053608A1 (es)
ZA (1) ZA200106811B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
US7273872B2 (en) * 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
US20090076059A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dianicline
JP5701607B2 (ja) 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
WO2010009775A1 (de) 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US9023854B2 (en) * 2007-12-07 2015-05-05 AbbVie Deutschland GmbH & Co. KG 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
JP5645217B2 (ja) * 2007-12-07 2014-12-24 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 5,6−二置換オキシンドール誘導体およびバソプレッシン依存性疾患を治療するためのこれらの使用
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
MY173229A (en) 2008-11-19 2020-01-07 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
EP2435080A2 (en) * 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
GB9301660D0 (en) * 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
JPH11512443A (ja) * 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
FR2761072B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de 2,3-dihydrofuro[3,2-b]pyridine, leur preparation et leur application en therapeutique
ZA984637B (en) * 1997-05-30 1998-12-21 Neurosearch As Spiro-quinuclidine derivatives their preparation and use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
KR20010102492A (ko) 2001-11-15
FR2790474B1 (fr) 2001-04-06
BG105828A (bg) 2002-03-29
HUP0201753A3 (en) 2004-12-28
EE200100470A (et) 2002-12-16
UA61164C2 (uk) 2003-11-17
WO2000053608A1 (fr) 2000-09-14
DK1161434T3 (da) 2003-05-26
SK284339B6 (sk) 2005-02-04
JP4806123B2 (ja) 2011-11-02
NO327119B1 (no) 2009-04-27
ATE231869T1 (de) 2003-02-15
EP1161434B1 (fr) 2003-01-29
AR022820A1 (es) 2002-09-04
UY26048A1 (es) 2000-09-29
HK1040398A1 (en) 2002-06-07
BR0008763A (pt) 2002-01-02
SK12422001A3 (sk) 2002-04-04
AU2922600A (en) 2000-09-28
BG65211B1 (bg) 2007-07-31
PL352330A1 (en) 2003-08-11
EE04497B1 (et) 2005-06-15
IL145150A (en) 2007-06-03
CN1137894C (zh) 2004-02-11
CN1343208A (zh) 2002-04-03
CA2372063A1 (en) 2000-09-14
CZ20013102A3 (cs) 2002-01-16
CA2372063C (en) 2011-01-11
ZA200106811B (en) 2002-08-19
AU764625B2 (en) 2003-08-28
FR2790474A1 (fr) 2000-09-08
RU2238273C2 (ru) 2004-10-20
KR20070086359A (ko) 2007-08-27
ES2191611T3 (es) 2003-09-16
HUP0201753A2 (en) 2002-09-28
US6538003B1 (en) 2003-03-25
PE20001543A1 (es) 2001-03-18
HRP20010655B1 (en) 2003-06-30
DE60001307D1 (de) 2003-03-06
NO20014270D0 (no) 2001-09-03
RS49997B (sr) 2008-09-29
US6908927B2 (en) 2005-06-21
NO20014270L (no) 2001-11-05
JP2002539129A (ja) 2002-11-19
HU228671B1 (en) 2013-05-28
US20030187012A1 (en) 2003-10-02
DE60001307T2 (de) 2003-12-11
MXPA01008972A (es) 2002-03-27
IL145150A0 (en) 2002-06-30
KR100768355B1 (ko) 2007-10-17
PL201683B1 (pl) 2009-04-30
CZ302259B6 (cs) 2011-01-19
HRP20010655A2 (en) 2002-08-31
ID30116A (id) 2001-11-08
YU59601A (sh) 2004-03-12
EP1161434A1 (fr) 2001-12-12
TR200102403T2 (tr) 2001-12-21
TWI222975B (en) 2004-11-01
HK1040398B (zh) 2003-07-18
NZ513561A (en) 2003-06-30

Similar Documents

Publication Publication Date Title
CO5160250A1 (es) Derivados de piridopiranoacepinas su procedimiento de sintesis y composiciones que los contienen
CO5310534A1 (es) Nuevos derivados de androstano anti-inflamatorios
AR076896A2 (es) Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados
ECSP941066A (es) Derivados de 1.5 benzodiazepina
RU2001123126A (ru) Производные пиридопираноазепинов, их получение и терапевтическое применение
CO5170534A1 (es) Derivados de fenil propionamida como activadores de la glucoquinasa
ES2192520T3 (es) Composicion farmaceutica.
RU2009105669A (ru) Способ получения 3-замещенных 2-амино-5-галогенбензамидов
CO5271665A1 (es) (compuestos de pirrolo [2,3-d] pirimidina
CO5700820A2 (es) Derivados de dioxan-2-alquilcarbamatos, su preparacion y su aplicacion en terapeutica
BR0309534A (pt) Composto, composição farmacêutica, e, uso de um composto
AR038383A1 (es) Compuesto inhibidor de la hepatitis c
CO4960658A1 (es) Derivados de acidos ariloxiarilsulfonilamino hidroxamicos
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
AR039698A1 (es) Agonistas de los receptores cannabinoides
AR044883A1 (es) Derivados del 8-aza-biciclo [3.2.1] octano y su uso como inhibidores de la recaptacion de neurotransmisores monoaminicos
AR036602A1 (es) Agonistas muscarinicos
ES2137512T3 (es) Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico.
CO5200762A1 (es) Preparacion de piperidin-4-onas sustituidas
CO4750656A1 (es) Derivados de 5-aril-3-(8-azabiciclo[3.2.1]oct-3-il)-1,3,4- oxadiazol-2 (3h)-ona, su preparacion y medicamentos que lo contienen
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
BR0114753A (pt) Processo para a preparação de compostos de bis-benzazolila
CO4940417A1 (es) DERIVADOS DE 2,3-DIHIDROFURO[3,2-b]PIRIDINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
CO4890850A1 (es) Derivados de 6-pirrolidin-2-ilpiridinas, su reparacion y preparacion en terapeutica.
FI873009A0 (fi) Foerfarande foer framstaellning av (2-dimetylaminoetyl)-/2-/(2-tiometylfenyl)-(fenylmetyl)/amino-2-oxoetyl /karbamater eller -karbamider.